Active specific immunotherapy

Mitchell MS, Harel W, Kan-Mitchell J, et al. Active specific immunotherapy of melanoma with allogeneic cell lysates. Rationale, results, and possible mechanisms of action. Ann NY Acad Sci 1993 690 153-166. 

T. Arlin, Z. Active specific immunotherapy in patients with melanoma. J. Clin. Invest. 1990, 86, 2136-2144. 

Hoover HC Jr, Surdyke MG, Dangel RB, Peters LC, Hanna MG Jr. Prospectively randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer. Cancer 1985 55(6) 1236 3. 

Fung P. Y. S. Madej M. Koganty R. R. Longenecker B. M. Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate. Cancer Res 1990, 50, 4308-4314. 

MacLean G. D. Reddish M. A. Longenecker B. M. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J Immunotherapy 1996,19,9-68. 

Conforti AM, Ollila DW, Kelley MC, et al. Update on active specific immunotherapy with melanoma vaccines. J Surg Oncol 1997 66 55-64. 

Morton DL, Foshag LJ, Hoon DS, et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy withanewpoly-valent melanoma vaccine. Ann Surg 1992 216 463. 

A large body of evidence supports the notion that both the adaptive and nonadaptive immune systems play an important role in the control of tumor progression in patients with malignant disease. These findings have provided the rationale for the development of active specific immunotherapy for the treatment of malignant disease. The enthusiastic application of active specific immunotherapy in a large number of patients has conclusively shown that ... 

The results of immunomonitoring assays in patients treated with active specific immunotherapy have poor, if any, predictive value of clinical responses. 

Active Specific Immunotherapy Based on MUCI Animal models... 

Rios, A., and Simmons, R. L., 1974, Active specific immunotherapy of minimal residual tumor Excision plus neuraminidase-treated tumor cells. Intern. J. Cancer 13 71. 

Diagnosis Be suspicious if an aerosol attack occurs in the form of yellow rain with droplets of yellow fluid contaminating clothing and the environment. Confirmation requires testing of blood, tissue and environmental samples. As for treatment, there is no specific antidote however, super-activated charcoal should be given orally if the toxin is swallowed. The only defense is to wear a protective mask and clothing during an attack. No specific immunotherapy or chemotherapy is available for use in the field. 

Active Non-Specific Immunotherapy - Active non-specific immunotherapy involves a general stimulation of the host s immuno system. Yashphe has recently written a very comprehensive review of this topic.32... 

---